RVNC — Revance Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $379.98m
- $637.94m
- $234.04m
- 19
- 40
- 53
- 30
Annual income statement for Revance Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.413 | 15.3 | 77.8 | 133 | 234 |
| Cost of Revenue | |||||
| Gross Profit | — | 10.6 | 54.4 | 80.9 | 160 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 165 | 288 | 352 | 475 | 551 |
| Operating Profit | -164 | -273 | -275 | -342 | -317 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -159 | -285 | -281 | -356 | -324 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -159 | -282 | -281 | -356 | -324 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -159 | -282 | -281 | -356 | -324 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -159 | -282 | -281 | -356 | -324 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.67 | -4.86 | -4.17 | -4.28 | -3.09 |